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Abstract
The objective of the study was to examine pregnancy outcomes
in women with systemic lupus erythematosus (SLE) and
population controls in Trinidad. We performed a cross-sectional
analysis of adverse outcomes in pregnancies of Afro-Caribbean
women with SLE and without SLE. One hundred and twenty-
two female adult cases of SLE and 203 neighbourhood age-
matched women without SLE were interviewed concerning
details of their reproductive history, and the anticardiolipin
antibody (ACL) status was established for women with SLE. A
total of 1,029 pregnancies were reported (356 by women with
SLE, 673 by women without SLE). In women with ≥ 1 pregnancy
the total number of pregnancies was similar in women with a
diagnosis of SLE and women without; however, a lower
proportion of women with SLE had ever been pregnant
compared with women without SLE (80% versus 91%, P =
0.002). In multivariate logistic regression analyses adjusted for
maternal age, district of residence, pregnancy order and
smoking, SLE pregnancies were more than twice as likely to end
in foetal death than non-SLE pregnancies (odds ratio (OR), 2.4;
95% confidence interval (CI), 1.2–4.7). This effect was driven
by a large increase in the odds of stillbirth (OR, 8.5; 95% CI,
2.5–28.8). The odds of early miscarriage (OR, 1.4; 95% CI,
0.6–3.1) and of mid-trimester miscarriage (OR, 1.9; 95% CI,
0.4–9.5) were higher, but were not statistically significantly
different, in SLE pregnancies than in non-SLE pregnancies. The
odds of ectopic pregnancy (OR, 7.5; 95% CI, 0.9–62.5) and of
preterm birth (OR, 3.4; 95% CI, 1.2–10.0) were higher in SLE
pregnancies conceived after diagnosis than in non-SLE
pregnancies. There was no evidence of raised levels of IgG or
IgM ACL among the majority (93/97 women, 96%) of SLE
cases who reported sporadic mid-trimester miscarriage or
stillbirth, although there was evidence of high levels of IgM and
IgG ACL among women reporting three or more miscarriages
and three consecutive miscarriages, and of raised IgG ACL
among those experiencing ectopic pregnancy. In conclusion, we
found evidence for a large increase in risk of stillbirth in the
pregnancies of Afro-Caribbean Trinidadian women with SLE
(not accounted for by high ACL status). There was some
evidence of an increased risk of preterm delivery and ectopic
pregnancy in pregnancies conceived after a diagnosis of
maternal SLE.
Introduction
Systemic lupus erythematosus (SLE) is a complex autoim-
mune disease that predominantly affects females of child-
bearing age (female:male ratio approximately 9:1), with both
genetic and environmental determinants, and is particularly
common in Afro-Caribbean populations. SLE has a well-recog-
nised association with second-trimester miscarriage; studies
have also examined other adverse pregnancy outcomes
including prematurity and pregnancy loss [1-16]. Some of
these studies, however, are based on small numbers and/or
tertiary referral centres with many high-risk patients, and few
studies involved a comparison group [2,8].
Risk factors that have been previously identified for adverse
pregnancy outcome in women with SLE (particularly second-
trimester miscarriage) include antibodies to phospholipids
(lupus anticoagulant and anticardiolipin antibodies), lupus
activity and renal disease [1-3,5-9,11,12,17,18]. Many studies
ACL = anticardiolipin antibody (subtypes IgM and IgG); Anti-ds DNA = Anti-double stranded DNA; APS/APL = Anti-Phospholipid Syndrome; 95% 
CI = 95% confidence interval; OR = odds ratio; SLE = systemic lupus erythematosus.Arthritis Research & Therapy    Vol 9 No 6    Molokhia et al.
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may underestimate the rates of early miscarriage, however, as
patients may not have been referred after a pregnancy was
lost.
Trinidad was selected as an ideal place for study of pregnancy
outcomes as large family sizes are common combined with a
young age of reproduction. There are no known previous such
studies in the Caribbean. There are no national data for Trini-
dad available on miscarriages, although data are provided on
other reproductive outcomes such as live births and stillbirths
[19]. At the last census in 2000, the population of Trinidad &
Tobago was 1.26 million. Estimating the prevalence of SLE in
Northern Trinidad is difficult as we do not have exact denomi-
nator data. Typical prevalence rates in Afro-Caribbean women
in the United Kingdom, however, are around 200 per 100,000
adult women, which are six to eight times higher than in Euro-
peans [20,21]. Preliminary work carried out by the authors
suggested there may be approximately 373 cases of SLE in
Northern Trinidad (see Discussion), with a population denom-
inator of approximately 170,000 adult females [22] – thus giv-
ing a crude SLE prevalence of approximately 219 per 100,000
in females in Trinidad.
Health services in Trinidad are mainly public sector with some
private hospitals and clinics. Primary healthcare services
include 102 nationwide health centres. Secondary healthcare
is available at eight district hospitals and three large govern-
ment hospitals in Port of Spain, San Fernando and Arima. Ter-
tiary healthcare is available in Port of Spain. One of the main
facilities is the Mount Hope Medical Complex, which houses a
340-bed general purpose hospital, including a 110-bed mater-
nity hospital. Overall there is reasonable access to healthcare,
even in low-income groups.
The aim of the study was to examine adverse pregnancy out-
comes (miscarriage, stillbirth, ectopic pregnancy and preterm
delivery) in a large group of Trinidadian Afro-Caribbean
women with SLE and without SLE.
Patients and methods
Study design
The study was a population-based questionnaire survey of
reproductive outcomes of adult Afro-Caribbean women living
in Northern Trinidad diagnosed with SLE and without SLE.
These women were identified for a case – control study of SLE
that was conducted from 1998 to 2002 [23]. We obtained
reproductive histories in addition to information on various life-
style factors and demographic factors, including socioeco-
nomic status, and contraceptive pill use. No women with SLE
or without SLE were pregnant at the time of interview. Serum
from 122 women with SLE was sent for IgG anticardiolipin
antibody (ACL) and IgM ACL assays at a standard UK labora-
tory. (The laboratory normal range for IgG ACL was 0.0–12.0
U/ml, and that for IgM ACL was 0.0–5.0 U/ml.)
Ascertainment of women with systemic lupus 
erythematosus
Cases were adult women with SLE, aged 18 years and older,
resident in northern Trinidad from 1998 to 2002 who were
selected according to the standard revised American Rheu-
matism Association 1982 criteria [24] through multiple
sources. The study was restricted to women of Afro-Carib-
bean ethnicity (this was because the original study design was
examining SLE risk in relation to African ancestry in Afro-Car-
ibbean populations, and other ethnic groups such as Indian or
Chinese show epidemiological evidence for increased risk of
SLE). In summary, surviving adult women with SLE were
ascertained from five sources from both the public sector and
the private sector: the lupus register at Port of Spain General
Hospital (started in 1992); the rheumatology, renal, and der-
matology outpatient departments from the two main hospitals
that serve the defined population of Northern Trinidad (Port of
Spain General Hospital and Mount Hope Hospital, Arima); a
systematic search of outpatient records plus hospital labora-
tory records of positive tests for antinuclear antibodies at the
two main hospitals to identify cases of SLE; Lupus Society
meetings and through advertisements in the quarterly newslet-
ter and television; and an immunology register compiled from
records for 1992–2000 that included cases diagnosed
through high (> 1:256) titres of antinuclear antibodies and
antidouble-stranded DNA antibodies and those patients with
positive histology from skin biopsies. Details of these registries
are described elsewhere [23].
More than 90% of patients with SLE registered with the Lupus
Society attended one of the two main hospitals servicing this
catchment area. Few patients had been seen exclusively pri-
vately (< 5%). We established that case records are available
for more than 90% of these patients and that these records
include adequate information on the clinical and laboratory
findings upon which the patient diagnosis was based. Both
hospitals were visited to assess the quality and completeness
of the records. When invited for interview, patients were also
asked to bring any private case records in their possession,
and these were used to validate clinical criteria and medical
history.
Ascertainment of women without systemic lupus 
erythematosus
For each case, randomly chosen households in the same
neighbourhood were sampled by the field team to obtain two
women without SLE, matched with the case patient for sex
and for 20-year age group (this was adjusted as the original
matching for 10-year age group led to many exclusions for
controls). For each case patient the interviewer drew a map,
compiled a list of 25 adjacent households and visited these
households in random order using random-number tables to
interview all eligible individuals in the same age – sex group as
the case. Where possible, a listing of the age, sex and ethnicity
of all household members was obtained and arranged inAvailable online http://arthritis-research.com/content/9/6/R124
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descending order of age. The interviewer then selected at ran-
dom (using printed tables) one suitable individual for interview
according to the numbers eligible. This was continued until eli-
gible controls had been obtained from at least two separate
households.
Patient interviews
Where possible, all cases identified through the hospital clin-
ics and lupus registers were telephoned and invited to partic-
ipate in the study. Where telephones were not listed, case
records and telephone directories were checked. We estab-
lished from preliminary studies that 80% of households had a
telephone. Where telephones were not available, invitations
about the study together with a study information sheet with
contact telephone number were sent to the participant's
address or were delivered by hand. Nonrespondents were
sent reminders or were revisited. All women were offered a
choice to be interviewed at home or in the project office using
a validated questionnaire that included demographic items,
socioeconomic indices in childhood and adult life, birth order,
medical history, and reproductive history. Detailed (self-
reported) information was collected on all pregnancies, includ-
ing date of pregnancy end, gestation and outcome of preg-
nancy. We did not have access to accurate birthweight
records so this parameter could not be studied. Pretesting of
the questionnaire was used to train research interviewers and
to refine ambiguous questions. Participants were paid travel
expenses, and were offered a complimentary full blood count,
cholesterol measurement, or membership to the Lupus Soci-
ety for 1 year. All reasons for nonresponse in relation to obtain-
ing the household listing or in relation to selecting suitable
control individuals were documented. Crude socioeconomic
data on status of nonresponders were compared with those of
responders where possible (type of housing, car and tele-
phone ownership). Up to two return visits were made at differ-
ent times of the day, including weekends and after working
hours, in order to interview potential control individuals. Blood
was taken for DNA and serum storage prior to analyses at the
time of interview.
Ethical approval was granted by the Ethics Committee of the
London School of Hygiene & Tropical Medicine and by the
Ministry of Health of the Republic of Trinidad & Tobago. All
participants provided informed consent for this study.
Pregnancy outcome: statistical analyses
The majority of the analyses described here are pregnancy
based. Women were excluded from this analysis if they were
aged younger than 18 years at interview (one woman with
SLE) or were too ill to participate (four women with SLE). The
outcomes of interest were live birth, preterm birth, miscarriage
(early and late), ectopic pregnancy, stillbirth, and foetal death
as a whole (comprising all miscarriage and stillbirth). The expo-
sure of interest was maternal SLE status. Three categories of
foetal death were used according to the reported gestation at
the end of the pregnancy: early (first-trimester) miscarriage (≤
12 completed weeks), late (mid-trimester) miscarriage (13–23
weeks), and stillbirth (≥ 24 weeks gestation). Preterm delivery
was defined as a livebirth that ended before 37 weeks of com-
pleted gestation.
The denominator for the analyses of early miscarriage was all
reported pregnancies; for late miscarriage, the denominator
included all pregnancies surviving more than 12 weeks; and
the denominator for stillbirth included all live and stillborn
babies. For analyses of ectopic pregnancy, the denominator
was all pregnancies; and for analyses of preterm delivery, the
denominator was all live births. Ectopic pregnancies were
excluded from all analyses of foetal death. Information on ter-
mination was incomplete as termination for nonmedical rea-
sons is illegal in Trinidad, and was therefore omitted from all
analyses. Multiple pregnancies (a total of five twin pregnan-
cies, which could only be identified for those women with ges-
tation over 24 weeks) were excluded from all analyses.
All analyses were carried out using STATA statistical software
(release 9.0, 2005; Stata Corporation, College Station, TX,
USA). All analyses were adjusted for maternal age at the time
of conception, for pregnancy order and for smoking. Although
the original design was matched on the neighbourhood of res-
idence, results were similar using matched or unmatched anal-
ysis – the latter results are therefore presented. The district of
residence, however, was included in all models since in the
original design women without SLE were matched to SLE
cases in the same neighbourhood as the SLE cases. Analyses
were performed using different markers of socioeconomic sta-
tus, including years of education and district of residence. The
unit of analysis was a pregnancy. The association between the
relevant pregnancy outcome and SLE status at time of survey
or between the relevant pregnancy outcome and SLE status at
time of conception was explored using logistic regression
analysis – effects on risk being estimated by odds ratios (ORs)
with 95% confidence intervals (CIs). Since women could have
more than one pregnancy in the analysis, a robust method
based on the 'sandwich estimate' [25] was used to compute
standard errors, with Wald tests used to test the statistical sig-
nificance of parameters [26].
Results
The response rate for eligible SLE cases in the case–control
study was 122/131 (93%). Two women with SLE refused to
participate and seven did not attend for interview. Of eligible
women without SLE, the response rate was 70% (203/290).
Initial comparison of nonresponders in women without SLE did
not show significant differences in age or socioeconomic sta-
tus. There was no association of district with risk of SLE.
Woman-based analyses
Table 1 presents data for the characteristics of the 122 female
participants with SLE and of the 203 women in theArthritis Research & Therapy    Vol 9 No 6    Molokhia et al.
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comparison group. There was no difference in socioeconomic
status between women with SLE and population controls at
the time of the survey (cases were matched on district of res-
idence); nor was there evidence of a difference in level of edu-
cation attained (P = 0.60), although there was some evidence
that a greater proportion of SLE cases had grown up in house-
holds lacking running water (a proxy measure of hygiene and
socioeconomic status in childhood) (P = 0.05). A lower pro-
portion of SLE cases reported they had ever been pregnant
than women without SLE (80% versus 91%, P  = 0.002),
although this was probably related to the fact that women with
SLE were less likely to have ever married or cohabited (P =
0.02). There was no difference in oral contraceptive use
between the two groups (P = 0.5). Among those women who
had ever used the oral contraceptive pill, there was no signifi-
cant difference in length of use between women with SLE (2.4
years; standard deviation, 4.0) and women without SLE (1.8
years; standard deviation, 3.3) (P = 0.08).
The reported reproductive histories of the 97 women with SLE
and the 184 women without SLE who had ever been pregnant
are presented in Table 2. The overall total number of pregnan-
cies reported per woman was very similar in the two groups,
and there was no evidence of a difference in mean age at first
pregnancy. There was a suggestion that women with SLE
were more likely to miscarry, and they appeared to have
greater risk of stillbirth. There was also a suggestion that
ectopic pregnancy was more common among women with
SLE, although numbers were extremely small. These out-
comes were explored in more detail in the multivariate, preg-
nancy-based analyses reported later in the text.
The majority (80%) of women diagnosed with SLE had con-
ceived their first pregnancy prior to their SLE diagnosis –
although, on average, the total number of pregnancies
reported by those whose first conception was prior to SLE
diagnosis was the same as that among women whose first
conception was after their SLE diagnosis (Table 2). The aver-
age age at first conception was significantly higher among
women whose first pregnancy was after their SLE diagnosis (P
< 0.001), as might be expected (Table 2).
Pregnancy-based analyses
Table 3 presents the characteristics of all reported singleton
pregnancies. The overall proportion of pregnancies ending
successfully in live birth was much lower among those
reported by women with SLE (73%, versus 83% among preg-
nancies conceived by women without SLE), particularly when
the pregnancies were conceived after SLE diagnosis (42%) –
although numbers in this latter group were small.
Overall 1.6% of all reported live births and stillbirths conceived
by women without SLE ended in stillbirth (Table 4). This is
comparable with the national stillbirth figure of 1.2% of all
births [19], suggesting that women without SLE in the present
study were representative of the general population – particu-
Table 1
Characteristics of female participants at survey, 1998–2002
Women with SLE (n = 122) Women without SLE (n = 203) P valuea
Age at survey 0.5
15–24 years 4 (3%) 12 (6%)
25–34 years 21 (17%) 31 (15%)
35–44 years 39 (32%) 77 (38%)
45–54 years 32 (26%) 43 (21%)
≥ 55 years 26 (21%) 40 (20%)
Mean (standard deviation) age at interview (years) 44.4 (11.6) 43.4 (12.1)
Education after 18 years 23 (19%) 29 (14%) 0.6
Running water aged 12 years 77 (63%) 149 (73%) 0.05
Ever smoked 10 (8%) 27 (13%) 0.3
Marital status 0.02
Ever married/cohabited 83 (68%) 161 (79%)
Other 39 (32%) 42 (21%)
Hysterectomy reported at survey 15 (12%) 22 (11%) 0.7
Ever used contraceptive pillb 66 (55%) 100 (51%) 0.5
Ever been pregnant 97 (80%) 184 (91%) 0.002
aFrom chi-squared test for heterogeneity, detecting differences between women with systemic lupus erythematosus (SLE) and those without SLE. 
bTwo women with SLE and seven women without SLE had missing values for this variable.Available online http://arthritis-research.com/content/9/6/R124
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Table 2
Reported pregnancy histories at the time of survey among women who had ever been pregnant
Ever pregnant women
with SLE (n = 97)
Ever pregnant women
without SLE (n = 184)
P valuea
Total number of reported pregnancies per woman 0.50
1 13 (13%) 20 (11%)
2 20 (21%) 36 (20%)
3 21 (22%) 47 (26%)
4 19 (20%) 29 (16%)
5 10 (10%) 23 (13%)
≥ 6 14 (14%) 29 (15%)
Mean (standard deviation) number of pregnancies 3.7 (2.0) 3.7 (2.4)
Mean (standard deviation) age at first pregnancy (years) 22.1 (4.8) 22.5 (4.8) 0.55
Ever had a live birth – total number of live births reported per woman 0.12
0 7 (7%) 2 (1%)
1 20 (21%) 34 (18%)
2 22 (23%) 40 (22%)
3 24 (25%) 51 (28%)
4 11 (11%) 25 (14%)
≥ 5 13 (13%) 32 (17%)
Median (P5–P95)b live births 2.5 (0–5) 3 (1–5)
Ever miscarried – total number of miscarriagesc reported per woman 0.07
0 51 (53%) 125 (68%)
1 30 (31%) 35 (19%)
2 11 (11%) 15 (8%)
≥ 3 5 (5%) 9 (5%)
Median (P5–P95)b miscarriagesc 0.5 (0–3) 0 (0–3)
Ever had a stillbirth – total number of stillbirths reported per woman 0.01
0 86 (89%) 175 (95%)
1 7 (7%) 9 (5%)
≥ 2 4 (4%) 0
Median (P5–P95)b stillbirths 0 (0–1.25) 0 (0–0.75)
Ever had an ectopic pregnancy 0.17
0 92 (95%) 180 (98%)
1 5 (5%) 3 (2%)
≥ 2 01  ( 0 . 5 % )
Median (P5–P95)b ectopic 0 (0–1) 0 (0–0)
Women with a SLE diagnosis only
First pregnancy before SLE diagnosis 78 (80%) - -
First pregnancy after SLE diagnosis 19 (20%)
Age (years) at first pregnancy
Mean (standard deviation) age at first pregnancy if before SLE diagnosis 22.1 (4.6) - -
Mean (standard deviation) age at first pregnancy if after SLE diagnosis 26.6 (7.0)
Number of reported pregnancies per woman
Mean (standard deviation) pregnancies whose first conception was before SLE 
diagnosis
3.7 (2.1) - -
Mean (standard deviation) pregnancies whose first conception was after SLE 
diagnosis
3.6 (2.7)
aFrom chi-squared test for heterogeneity, detecting differences between women with systemic lupus erythematosus (SLE) and those without SLE. 
bFifth to 95th centiles – the central 90% of the distribution. c Includes missed abortions (missed miscarriages) and blighted ova.Arthritis Research & Therapy    Vol 9 No 6    Molokhia et al.
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Table 3
Characteristics of all reported singleton pregnanciesa
Mother ever diagnosed with SLE Mother never diagnosed
with SLE
Pregnancies conceived 
before mother's SLE 
diagnosis
Pregnancies conceived 
after mother's SLE 
diagnosis
All pregnancies conceived 
by mothers ever diagnosed 
with SLE
Total number of pregnancies 274 (100%) 78 (100%) 352 (100%) 667 (100%)
Mean (standard deviation) 
maternal age at conception
25.0 (5.5) 30.1 (5.6) 25.6 (5.8) 26.3 (6.1)
Pregnancy type
Live birth 224/274 (81.8%) 33/78 (42.3%) 257/352 (73.0%) 553/667 (82.9)
Foetal death 47/274 (17.2%) 43/78 (55.1%) 90/352 (25.6%) 109/667 (16.3%)
First-trimester miscarriage 
(0–12 weeks)b
28/274 (10.2%) 34/78 (43.6%) 62/352 (17.6%) 90/667 (13.4%)
Mid-trimester miscarriage 
(13–23 weeks)b
3/259 (1.2%) 4/49 (8.2%) 7/315 (2.2%) 9/605 (1.5%)
Miscarriage missing 
gestation
3/274 (1.1%) 1/78 (1.3%) 4/352 (1.1%) 1/667 (0.1%)
Stillbirth (≥ 24 weeks)c 13/237 (5.5%) 4/37 (10.8%) 17/274 (6.2%) 9/562 (1.6%)
Ectopic pregnancy 3/274 (1.1%) 2/78 (2.6%) 5/352 (1.4%) 5/667 (0.7%)
Reported gestation of live 
births (completed weeks)
All pregnancies ending in 
live birth
224 (100%) 33 (100%) 257 (100%) 553 (100%)
< 24 weeks 5 (2.2%) 3 (9.1%) 8 (3.1%) 20 (3.6%)
24–31 weeks 2 (0.9%) 3 (9.1%) 5 (2.0%) 2 (0.4%)
32–36 weeks 5 (2.2%) 1 (3.0%) 6 (2.3%) 4 (0.7%)
All preterm (< 37 weeks) 12 (5.4%) 7 (21.2%) 19 (7.4%) 26 (4.7%)
37–42 weeks 212 (94.6%) 26 (78.8%) 238 (92.6%) 526 (95.1%)
42–46 weeks 0 (0%) 0 (0%) 0 1 (0.2%)
Reported gestation of foetal 
deaths (completed weeks)
All pregnancies ending in 
foetal deathb
47 (100%) 43 (100%) 90 (100%) 109 (100%)
< 8 weeks 17 (36.2%) 25 (58.1%) 42 (46.7%) 63 (57.8%)
8–12 weeks 11 (23.4%) 9 (20.9%) 20 (22.2%) 28 (25.7%)
13–15 weeks 2 (4.3%) 0 (0%) 2 (2.2%) 4 (3.7%)
16–23 weeks 1 (2.1%) 4 (9.3%) 5 (5.6%) 5 (4.6%)
24–36 weeks 6 (12.7%) 4 (9.3%) 10 (11.1%) 4 (3.7%)
≥ 37 weeks 7 (14.9%) 0 (0%) 7 (7.7%) 3 (2.8%)
Missing gestation category 3 (6.4%) 1 (2.3%) 4 (4.4%) 2 (1.8%)
aTwin pregnancies excluded. bFour pregnancies ending in miscarriage have the gestational age missing (three conceived prior to systemic lupus 
erythematosus (SLE) diagnosis; one conceived after SLE diagnosis). cOne woman without SLE had missing stillbirth gestation.Available online http://arthritis-research.com/content/9/6/R124
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larly since the stillbirths in the Trinidad population survey were
classified as foetal death at ≥ 28 weeks, so the rates of still-
birth defined as foetal death at ≥ 24 weeks as in the study will
be higher.
Table 4 presents multivariate logistic regression analyses of
foetal death, adjusted for district of residence, maternal age,
pregnancy order and smoking.
Overall foetal death was over twice as likely among pregnan-
cies conceived by women with SLE than women without SLE
(OR, 2.4; 95% CI, 1.2–4.7). There was, however, no strong
evidence of an effect of SLE on risk of early miscarriage (OR,
1.4; 95% CI, 0.6–3.1, regardless of time of diagnosis). Odds
of late miscarriage were almost doubled among pregnancies
conceived by women with SLE than those of women without
SLE (OR, 1.9; 95% CI, 0.4–9.5), although the numbers of
cases were extremely small and this result was not statistically
significant. There was strong evidence of an effect of SLE on
stillbirth: the odds of stillbirth were over eight times higher
among pregnancies conceived by women diagnosed with SLE
compared with that among pregnancies conceived by women
never diagnosed with SLE (OR, 8.5; 95% CI, 2.5–28.8).
Once adjusted for maternal age, which acted as a strong con-
founder, there was no strong evidence to suggest a difference
in risk of foetal death between pregnancies conceived before
and after SLE diagnosis (Table 4), although the numbers of
cases among pregnancies conceived after SLE diagnosis
were really too small to draw meaningful conclusions.
After adjustment for district of residence, maternal age, preg-
nancy order and smoking, there was evidence that ectopic
pregnancy was over three-and-a-half times as likely among
pregnancies conceived by women with SLE as those con-
ceived by women without SLE (OR, 3.6; 95% CI, 0.7–18.7).
This effect appeared much stronger among pregnancies con-
ceived after SLE diagnosis (OR, 7.5; 95% CI, 0.9–62.5).
These estimates were not statistically significant but the num-
bers of cases were extremely small, and power was therefore
consequently low (Table 5).
After adjustment for district of residence, maternal age, preg-
nancy order and smoking, the odds of preterm delivery were
also raised – pregnancies conceived by women with SLE
being an estimated 50% more likely to be preterm than those
conceived by women without SLE (OR, 1.5; 95% CI, 0.7–3.2)
(Table 5). This effect again appeared much stronger among
pregnancies conceived after SLE diagnosis (OR, 3.4; 95% CI,
1.2–10.0).
Among women who reported three or more pregnancies, there
was no apparent difference in risk of three or more miscar-
riages (any gestation) between women with SLE and without
SLE (6/64 (9.4%) versus 9/128 (7.0%), respectively; P  =
0.6). Nor was there evidence of a difference in risk of three
Table 4
Foetal deatha among pregnanciesb reported by Trinidadian women by systemic lupus erythematosus (SLE) status
Early miscarriagea,c
(0–12 weeks)
Late miscarriagea,d
(13–23 weeks)
All miscarriagea,e
(0–23 weeks)
Stillbirthf (≥ 24 weeks) All foetal deathg
n (%) Adjusted ORh
(95% CI)
n (%) Adjusted ORh 
(95% CI)
n (%) Adjusted ORh 
(95% CI)
n (%) Adjusted ORh 
(95% CI)
n (%) Adjusted ORh 
(95% CI)
Mother not 
diagnosed 
with SLE
90 
(13.5%)
1.0
(-)
9
(1.8%)
1.0
(-)
100i 
(15.0%)
1.0
(-)
9 
(16.0%)
1.0
(-)
109 
(16.3%)
1.0
(-)
Mother 
diagnosed 
with SLE
62 
(17.6%)
1.4
(0.6–3.1)
7
(2.2%)
1.9
(0.4–9.5)
73j 
(20.7%)
1.6
(0.8–3.5)
17 
(6.2%)
8.5
(2.5–28.8)
90j 
(25.6%)
2.4
(1.2–4.7)
Pregnancy 
conceived 
prior to SLE 
diagnosis
28 
(8.0%)
1.6
(0.7–3.7)
3
(1.0%)
2.2
(0.4–10.9)
34k 
(9.7%)
1.9
(0.8–4.2)
13 
(4.7%)
8.3
(2.3–29.2)
47k 
(13.3%)
2.6
(1.3–5.4)
Pregnancy 
conceived 
after SLE 
diagnosis
34 
(9.7%)
0.4
(0.1–2.6)
4
(1.2%)
-l 39m 
(11.1%)
0.3
(0.0–2.5)
4
(1.4%)
9.8
(1.7–58.0)
43m 
(12.2%)
1.1
(0.3–3.3)
aIncludes missed abortions and blighted ova. bAll analyses exclude ectopic and twin pregnancies. cDenominator for all analyses having early (first-
trimester) miscarriage as the outcome is all reported pregnancies. dDenominator for all analyses having late (mid-trimester) miscarriage as the 
outcome is all pregnancies surviving 13 weeks gestation or more. eDenominator for all analyses having all miscarriage as the outcome is all 
pregnancies. fDenominator for all analyses having stillbirth as the outcome is all live births and stillbirths (excluding miscarriages). gDenominator for 
all analyses having all foetal death as the outcome is all pregnancies. hAll odds ratios (ORs) adjusted for district of residence, maternal age, 
pregnancy order and smoking 95% CI, 95% confidence interval. iOne miscarriage has missing gestation; excluded from analyses of early/late 
miscarriage. jFour miscarriages have missing gestation; excluded from analyses of early/late miscarriage. kThree miscarriages have missing 
gestation; excluded from analyses of early/late miscarriage. lModel cannot be fitted – all four cases have missing maternal age (strong predictor of 
miscarriage, which is needed in the model). mOne miscarriage has missing gestation.Arthritis Research & Therapy    Vol 9 No 6    Molokhia et al.
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consecutive miscarriages in this group (4/64 (6.3%) among
women with SLE versus 7/128 (5.5%) among women without
SLE, P = 0.8). The numbers, however, were too small to draw
firm conclusions.
Our analyses of IgG ACL levels or IgM ACL levels among
women with SLE did not show evidence of high IgG ACL or
IgM ACL associated with sporadic mid-trimester miscarriage.
There was evidence, however, of an association of high titres
of IgG ACL and IgM ACL among the small number (n = 5, 5%)
of women with SLE reporting three or more miscarriages (P =
0.001 and P = 0.009, respectively, when compared with (nor-
mal) expectation), and among women with SLE reporting three
consecutive miscarriages (P = 0.03 and P = 0.05, respec-
tively). Of those women with SLE who experienced a stillbirth,
1/17 (6%) had high IgM ACL and 3/17 (18%) had high IgG
ACL. We also found an association of high titres of IgM ACL
with preterm delivery (P = 0.013) and with ectopic pregnancy
(0.05), although this was based on small numbers. Elevated
IgG ACL levels were also associated with increased risk of
ectopic pregnancy (P = 0.03).
Regression analyses adjusting for other socioeconomic indi-
cators such as years of education or previous foetal death
made little difference to the overall results reported above. Fur-
thermore, the results were largely unchanged when we used
the Sydney antiphospholipid syndrome criterion of loss at >
10 weeks gestation to define the reported foetal losses in this
study.
Discussion
The present study is the first to examine pregnancy outcome
in women with SLE in Trinidad, where large family sizes and
early age of reproduction make it an ideal environment to study
the relationship between SLE and foetal outcomes. Access to
healthcare was equal for women with SLE and for women in
the comparison group, even in low-income groups.
We found that pregnancies conceived by Afro-Caribbean
Trinidadian women with SLE were more likely to end in foetal
death (OR, 2.4; 95% CI, 1.2–4.7). The strongest effect was
on risk of stillbirth, where pregnancies conceived by women
with SLE were greater than eight times more likely to end in
this way (OR, 8.5; 95% CI, 2.5–28.8). There was also some
evidence of an increased risk of ectopic pregnancy among
pregnancies conceived by women with SLE. Finally, we found
that pregnancies conceived by women with SLE also
appeared more likely to end in preterm delivery. This effect
was strongest among those conceived after SLE diagnosis,
which were greater than three times more likely to end in pre-
term delivery than those conceived by women without SLE
(OR, 3.4; 95% CI, 1.2–10.0).
Details regarding pregnancy outcomes in general within Trini-
dad are unavailable, but recent national data suggest that the
overall crude live birth rate of 18,490 per 629,315 (2.9%) total
female population [19] is approximately twice as high as in
North America [27]. At the time of writing there were no
national data available on miscarriage in Trinidad, although the
national stillbirth rate was estimated as 1.2% total births,
which is slightly higher than European figures (approximately
0.5% of total births around the time of this study) [28].
The live birth rate (42%) among women conceiving after a
diagnosis of SLE is lower than that reported in other studies
(84–87%) [1,3,5]; however, this may reflect higher disease
activity and comorbidity in Trinidad. Furthermore, termination
of pregnancy is currently illegal in Trinidad and therefore is
likely to have been misreported as miscarriage – combined
with the fact that most foetal deaths were reported as first-tri-
mester miscarriage (17.6%), this misreporting might suggest
that the higher pregnancy loss rate in our study could be
explained by a higher proportion of induced abortion in this
age group. Our findings for foetal death overall (24% in
women diagnosed with SLE and 16% in women without SLE)
is slightly higher than those in other studies (7–16%) [1,3,5,8].
Early foetal loss may not, however, have been counted in these
studies. Few other studies have reported on ectopic preg-
nancy in relation to SLE (or it is not clear whether ectopic was
included as 'foetal loss') – but an increased risk of ectopic
Table 5
Ectopic pregnancy and live-born preterm delivery among all pregnancies reported by Trinidadian women by systemic lupus 
erythematosus (SLE) status
Ectopic pregnancya Preterm delivery among live-born infantsb
n (prevalence %) Adjusted odds ratio
(95% confidence interval)
n (prevalence %) Adjusted odds ratio
(95% confidence interval)
Mother not diagnosed with SLE 5 (0.7%) 1.0 (-) 26 (4.7%) 1.0 (-)
Mother diagnosed with SLE 5 (1.4%) 3.6 (0.7–18.7) 19 (7.3%) 1.5 (0.7–3.2)
Pregnancy conceived prior to SLE diagnosis 3 (0.8%) 3.1(0.5–17.9) 12 (4.7%) 1.2(0.5–2.8)
Pregnancy conceived after SLE diagnosis 2 (0.6%) 7.5 (0.9–62.5) 7 (2.7%) 3.4 (1.2–10.0)
aDenominator for all analyses having ectopic pregnancy as the outcome is all reported pregnancies; adjusted for district of residence, maternal age 
and smoking. bDenominator for all analyses having preterm delivery as the outcome is all live births (excluding foetal death); adjusted for adjusted 
for district of residence, maternal age and smoking.Available online http://arthritis-research.com/content/9/6/R124
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pregnancy was found in SLE patients in one study that did,
based on a study of only 17 women (42 pregnancies) with
SLE [29]. The increased risk of ectopic pregnancy is possibly
explained by reduced tubal motility.
First-trimester miscarriage rates are reported as 18% in
women with SLE and 13% in women without SLE, although
these may be overestimated values owing to the inclusion of
induced abortions, as discussed above. North American stud-
ies report first-trimester miscarriage as between 7% and 10%
based on moderate numbers of pregnancies in women with
SLE (63–267 pregnancies) [1,3,5]. Other European studies
have reported similar proportions to those found here. Evi-
dence of first-trimester miscarriage has been reported as 5%
in a cohort of 46 women with SLE (60 pregnancies); however,
this was in a tertiary centre with intensive management proto-
col for these high-risk pregnancies [6]. A study in France also
estimated a spontaneous miscarriage rate of 16% in European
women with SLE in 62 pregnancies (38 women) [12],
although this included cases with SLE nephropathy.
Spontaneous (first and second) miscarriage rates in pregnant
women from Saudi Arabia with lupus nephropathy (inactive
and active) are reported as between 25% and 32%, with
higher rates in patients with antibodies to phospholipids,
although this study included only 24 patients [10].
High stillbirth rates in women with SLE have been reported in
a number of other studies, with particular high risk in patients
with lupus nephritis and/or altered immunological profiles
including antiphospholipid syndrome [5,10,12,16,17]. Some
studies include a definition of stillbirth as spontaneous abor-
tion at gestation ≥ 20 weeks [12,17], however, which will
inflate the estimates. In a study that defined stillbirth as spon-
taneous abortion at > 24 weeks (as used here), the prevalence
is estimated as 3/19 (16%) pregnancies in women with lupus
nephritis. Risk of stillbirth also appears to be increased in
women who became pregnant after SLE was diagnosed (3/44
(6.8%) compared with one out of 10 pregnancies before SLE
was diagnosed) [7]. In general these figures are difficult to
interpret as estimates are based on very low numbers studied,
but the general finding of an increased risk of stillbirth is similar
to that reported here.
Other studies have identified risk of preterm birth in women
with SLE [6-9,12], although in some cases prematurity can be
medically induced due to complications such as maternal
preeclampsia [14]. We did not analyse cause of preterm birth
separately in this study.
Although the present study showed an important relationship
between SLE and both foetal death and preterm birth, the
study does have limitations, which need to be considered.
First, we were only studying women with SLE who had sur-
vived, and it is unknown what the reproductive outcomes of
those (more severe cases) who died before survey might have
been, and whether this might have impacted onto the results.
Next, there was a differential response rate in cases (93%)
and control individuals (70%) in the case – control study from
which these data came; however, analyses of socioeconomic
status such as car and home ownership did not differ between
control individuals who agreed to participate and those that
refused. It is possible that there may be bias from residual dif-
ferences between controls who responded and those that did
not; however, after obtaining a household listing of all inhabit-
ants, a strict protocol was followed to identify a possible con-
trol. Every attempt was made to ensure that selection included
working cases (up to three calls were made to identify eligible
control individuals at different times of the day and weekends).
No SLE cases or controls were excluded because they were
pregnant at the time of the survey.
In epidemiological studies, the capture – recapture technique
examines the degree of overlap between two (or more) meth-
ods of ascertainment and uses a simple formula to estimate
the predicted total size of the population. From capture –
recapture methods, we estimate a total of 373 cases of SLE
are resident in Northern Trinidad; this includes both sexes. In
reality, this is likely to be an underestimate as the probability of
being on the dermatology register and on the books of the
Lupus Society is associated with one another. Assuming 90%
of SLE cases are female, we estimate a total of 335 female
adult cases in Northern Trinidad. Allowing for incorrect
addresses, exclusions on nonAfro-Caribbean individuals and
deaths, the total estimated number of eligible SLE cases in
Northern Trinidad is 167, of whom we have ascertained 122
(73%).
Although there is potential over-reporting of 'miscarriage', as
termination for nonmedical reasons is illegal, this is unlikely to
be differential between women with SLE and women without
SLE. We are aware that this misclassification is likely to inflate
estimates of foetal loss, particularly first-trimester miscarriage.
Our analyses did not show evidence of either high titres of IgG
ACL or IgM ACL with sporadic mid-trimester miscarriage, foe-
tal loss, or stillbirth among SLE cases. There was evidence of
an association of high titres of IgG ACL and IgM ACL among
women reporting three or more miscarriages, and among
women with three consecutive miscarriages, but this was
experienced by just five of the 97 women with SLE who
reported ever being pregnant. We also found an association
of high IgM ACL and IgG ACL with ectopic pregnancy,
although this was based on small numbers, and an association
of high IgM ACL with preterm delivery. Treatment of women
with SLE during pregnancy with aspirin and/or heparin is not,
however, standard clinical practice in Trinidad. These findings
suggest that raised ACL antibodies cannot explain the results
for foetal death reported in the present paper, although theArthritis Research & Therapy    Vol 9 No 6    Molokhia et al.
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investigation of the role of ACL antibodies in preterm and
ectopic pregnancies warrants further attention.
Only 27/122 (22%) women who had ever been pregnant had
ever had a history of nephritis; however, specific information at
time of pregnancy was not available. No women without SLE
had documented renal involvement. In any case, adjusting for
history of renal involvement in the analyses made little differ-
ence. The percentage of immunosuppressive medication in
women with SLE treated with corticosteroids, treated with
other immunosuppressive medication, and treated with nons-
teroidal antiinflammatory drugs was 96%, 84% and 52%,
respectively – compared with values for control individuals of
4%, 16% and 48%, respectively. The prevalence of diagnosed
hypertension was higher in control individuals than in cases
(56% versus 44%), although this was not significant.
Conclusion
This well-conducted large population-based case-control
study of SLE provided data on 1,029 pregnancies, which
allowed us to examine adverse pregnancy outcomes in a sys-
tematic way. In women with SLE, we found a significantly
increased risk for still birth and all foetal death (not accounted
for by raised titres of ACL). We also found evidence for
increased (nonsignificant) risk of all miscarriage, and ectopic
pregnancies. Risk of preterm birth was significantly increased
among pregnancies conceived after SLE diagnosis.
Further studies may help clarify whether ectopic pregnancy
risk is raised in women with SLE, and the role of ACL in pre-
term and ectopic pregnancies. Women with SLE known to
have APL syndrome which is associated with recurrent fetal
loss and preterm delivery may benefit from antithrombotic
treatment including low dose aspirin [31], where early identifi-
cation of patients of particular risk (e.g. APL syndrome) for
closer patient management between rheumatologist and
obstetrician may help improve outcomes further. We suggest
further work could be carried out in monitoring of high obstet-
ric risk in women with SLE.
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